A carregar...
CRISPR/Cas9‐mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse
The X‐linked genetic bleeding disorder caused by deficiency of coagulator factor IX, hemophilia B, is a disease ideally suited for gene therapy with genome editing technology. Here, we identify a family with hemophilia B carrying a novel mutation, Y371D, in the human F9 gene. The CRISPR/Cas9 system...
Na minha lista:
Publicado no: | EMBO Mol Med |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
John Wiley and Sons Inc.
2016
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5125832/ https://ncbi.nlm.nih.gov/pubmed/26964564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201506039 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|